Definium Therapeutics, Inc. (DFTX)
NASDAQ: DFTX · Real-Time Price · USD
45.66
-0.32 (-0.70%)
At close: Jul 15, 2026, 4:00 PM EDT
45.58
-0.08 (-0.18%)
After-hours: Jul 15, 2026, 4:47 PM EDT
Definium Therapeutics Employees
As of December 31, 2025, Definium Therapeutics had 106 total employees, including 105 full-time and 1 part-time employees. The number of employees increased by 32 or 43.24% compared to the previous year.
Employees
106
Change (1Y)
32
Growth (1Y)
43.24%
Revenue / Employee
n/a
Profits / Employee
-$2,240,972
Market Cap
6.06B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 106 | 32 | 43.24% | 105 | 1 |
| Dec 31, 2024 | 74 | 17 | 29.82% | 74 | 0 |
| Dec 31, 2023 | 57 | 9 | 18.75% | 57 | 0 |
| Dec 31, 2022 | 48 | 7 | 17.07% | 48 | 0 |
| Dec 31, 2021 | 41 | 19 | 86.36% | 41 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| PTC Therapeutics | 991 |
| Travere Therapeutics | 497 |
| Xenon Pharmaceuticals | 370 |
| Scholar Rock Holding | 289 |
| Cogent Biosciences | 258 |
| CG Oncology | 142 |
| Erasca | 103 |
| Dianthus Therapeutics | 92 |
DFTX News
- 1 day ago - Definium Therapeutics announces results from healthcare claims study in GAD - TheFly
- 1 day ago - New Healthcare Claims Study Published in CNS Spectrums Finds High Rates of Treatment Switching, Discontinuation, and Prolonged Gaps in Care Among Patients with Generalized Anxiety Disorder (GAD) - Business Wire
- 7 days ago - Definium Therapeutics price target raised to $60 from $30 at Stifel - TheFly
- 9 days ago - Definium Therapeutics Announces New Employee Inducement Grants - Business Wire
- 15 days ago - Definium Therapeutics price target lowered to $58 from $60 at Canaccord - TheFly
- 19 days ago - A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year - PRNewsWire
- 20 days ago - Definium Therapeutics, Inc. Announces Closing of $805 Million Upsized Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares - Business Wire
- 20 days ago - Biotech ETF Index Surges 10% After Rebalance - ETF Trends